Sanofi Reports FDA's Acceptance of BLA for MenQuadfi to Prevent Meningococcal Meningitis
Shots:
- The FDA’s acceptance of BLA for review follows P-II & P-III study assessing MenQuadfi in patients aged ≥ 2yrs. conducted in the US
- MenQuadfi is currently evaluated in P-II & P-III studies in the US- EU- Asia & Latin America with an additional P-III studies in Africa in patients ranging from infants 6 weeks of age to older adults
- Sanofi’s MenQuadfi is a meningococcal (Groups A- C- Y- W) polysaccharide-tetanus toxoid conjugate vaccine with an ability to protect individuals from meningococcal meningitis with its expected PDUFA date as April 25- 2020
Click here to read full press release/ article | Ref: Sanofi | Image: Chattanooga Times Free Press
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
